Patient Guide: A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 18 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06212752
Status: ACTIVE_NOT_RECRUITING
Condition: Metastatic Non-small Cell Lung Cancer
Phase: PHASE3

Where You Can Participate

This study is available at 18 locations across the country.

Top locations include:
  • • Toyoake, Aichi
  • • Kurume, Fukuoka
  • • Otashi, Gunma
  • • And 15 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension - Join Clinical Trial NCTNCT06212752

How to Join This Clinical Trial - NCTNCT06212752

Learn how to participate in this PHASE3 trial studying an investigational therapy for Metastatic Non-small Cell Lung Cancer. Current status: ACTIVE_NOT_RECRUITING.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Metastatic Non-small Cell Lung Cancer. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Metastatic Non-small Cell Lung Cancer
Treatment Being Tested
Investigational treatment
Study Phase
PHASE3 - Large-scale efficacy study
Enrollment Status
ACTIVE_NOT_RECRUITING
Study Identifier
NCTNCT06212752 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 18 locations. Find a study site near you:

Clinical Research Site

Toyoake, Aichi 470-1192 - Japan

Status: Contact for availability

Clinical Research Site

Kurume, Fukuoka 830-0011 - Japan

Status: Contact for availability

Clinical Research Site

Otashi, Gunma 373-8550 - Japan

Status: Contact for availability

Clinical Research Site

Sapporo, Hokkaido 003-0804 - Japan

Status: Contact for availability

Clinical Research Site

Yokohama, Kanagawa 236-0051 - Japan

Status: Contact for availability

Clinical Research Site

Natori, Miyagi 981-1293 - Japan

Status: Contact for availability

Clinical Research Site

Sendai, Miyagi 9800873 - Japan

Status: Contact for availability

Clinical Research Site

Kurashiki, Okayama 710-8602 - Japan

Status: Contact for availability

Clinical Research Site

Hirakata, Osaka 573-1191 - Japan

Status: Contact for availability

Clinical Research Site

Takatsuki, Osaka 569-8686 - Japan

Status: Contact for availability

And 8 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE3 clinical trial for Metastatic Non-small Cell Lung Cancer:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships